Antibody variants composition

Patent metadata

Field	Value
Publication number	US-9556279-B2
Application number	US-201113038576-A
Country	US
Kind code	B2
Filing date	Mar 2, 2011
Priority date	Mar 2, 2010
Publication date	Jan 31, 2017
Grant date	Jan 31, 2017

Abstract

Among N-glycoside-linked sugar chains which are bound to the Fc region of an antibody, sugar chains which are bound to Asn at position 297 relates to the activity and stability of the antibody in blood, but there is a possibility that extra sugar chains bound to the amino acid residues at positions other than 297 have influences upon the antibody constant region-mediated activity and a possibility of causing a problem of uniformity as a therapeutic antibody preparation. Accordingly, among N-glycoside-linked sugar chains which bind to the Fc region of the antibody, a method for controlling extra sugar chains which are bound to Asn residues at positions other than position 297 according to the EU index is required. The present invention provides an antibody variant composition, comprising amino acid residues of an Asn-X-Ser/Thr (X represents an amino acid residue other than Pro) sequence at positions other than positions 297 to 299 according to the EU index in an Fc region of a human IgG antibody, in which at least one amino acid substitution selected from an amino acid substitution of Asn to other amino acid residue, an amino acid substitution of X to Pro and an amino acid substitution of Ser/Thr to other amino acid residue is carried out, and a fragment of the antibody variant composition.

First claim

What is claimed is:

1. A composition comprising antibodies having an Fc region, wherein said Fc region comprises the amino acid sequence of SEQ ID NO: 1 but with one or more amino acid substitutions selected from the group consisting of:
substitution of position 162 in SEQ ID NO: 1 with a residue other than Asn;
substitution of position 163 in SEQ ID NO: 1 with a Pro or Ala residue;
substitution of position 164 in SEQ ID NO: 1 with a residue other than Ser;
substitution of position 109 in SEQ ID NO: 1 with a Tyr residue; and
substitution of position 167 in SEQ ID NO: 1 with a Gln, Asn, Asp or Phe residue.

2. The composition according to claim 1 , wherein said Fc region comprises the amino acid sequence of SEQ ID NO: 1 but with one or more amino acid substitutions selected from the group consisting of:
substitution of position 162 in SEQ ID NO: 1 with a Gly, Ala, Val, Leu, Ile, Met, Pro, Asp, Gln, Glu, Lys, Arg, His, Phe, Tyr or Trp residue;
substitution of position 163 in SEQ ID NO: 1 with a Pro residue; and
substitution of position 164 in SEQ ID NO: 1 with a Leu, Asn, Asp, Lys, Phe, Tyr or Trp residue.

3. The composition according to claim 1 , wherein said Fc region comprises the amino acid sequence of SEQ ID NO: 1 but with the following amino acid substitutions:
(a) substitution of position 162 in SEQ ID NO: 1 with a residue other than Asn; and
(b) one or more substitutions selected from the group consisting of:
substitution of position 163 in SEQ ID NO: 1 with a Pro or Ala residue;
substitution of position 164 in SEQ ID NO: 1 with a residue other than Ser;
substitution of position 109 in SEQ ID NO: 1 with a Tyr residue; and
substitution of position 167 in SEQ ID NO: 1 with a Gln, Asn, Asp or Phe residue.

4. The composition according to claim 1 , wherein said antibodies comprise a CH1 domain and a hinge domain, and wherein the sequences of the CH1 domain and hinge domain of said antibodies are the same as the sequences of the CH1 domain and hinge domain of human IgG1, respectively.

Assignees

• Niwa Rinpei
• Tsuchiya Mami
• Kyowa Hakko Kirin Co Ltd

Inventors

• Niwa Rinpei
• Tsuchiya Mami

Classifications

• C07K2317/734

  Complement-dependent cytotoxicity [CDC] · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K2317/526

  CH3 domain · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title